OBJECTIVE: HIV-infected people are at increased risk of cancers of infectious origin. We estimated the burden of cancer attributable to infections among HIV-infected people in the United States in 2008. DESIGN: Incidence rates for cancer sites associated with infections were estimated from record linkage between HIV/AIDS registries and cancer registries. METHODS: Rates were applied to estimates of the population living with diagnosed HIV in the United States in 2008 to obtain the number of incident cancer cases. Site-specific attributable fractions and corresponding 95% confidence intervals (CIs) were estimated from infection prevalence among cancer cases. Infection prevalence data were derived from literature review of case series. RESULTS: Of an estimated 6200 incident cancer cases (95% CI 6000-6500), 2500 (95% CI 2400-2700) were attributable to infection (attributable fraction = 40%, 95% CI 39-42). The most important infections were Kaposi sarcoma herpes virus, Epstein-Barr virus, and human papillomavirus, which together were responsible for 2200 new cancer cases (95% CI 2100-2400), mainly Kaposi sarcoma, lymphomas, and ano-genital cancers. The attributable fraction in HIV-infected people was highest in the age group 20-29 years (69%, 95% CI 65-72). MSM were the HIV transmission group with the highest attributable fraction (48%, 95% CI 46-50), due to the high incidence of both Kaposi sarcoma and anal cancer. CONCLUSION: The very high fraction of cancer attributable to infection in HIV-infected people points to special opportunities to prevent these cancers, that is, avoidance, detection, and early treatment of cancer-associated infections, and universal early detection and uninterrupted treatment of HIV infection to avoid immunosuppression.
OBJECTIVE:HIV-infected people are at increased risk of cancers of infectious origin. We estimated the burden of cancer attributable to infections among HIV-infected people in the United States in 2008. DESIGN: Incidence rates for cancer sites associated with infections were estimated from record linkage between HIV/AIDS registries and cancer registries. METHODS: Rates were applied to estimates of the population living with diagnosed HIV in the United States in 2008 to obtain the number of incident cancer cases. Site-specific attributable fractions and corresponding 95% confidence intervals (CIs) were estimated from infection prevalence among cancer cases. Infection prevalence data were derived from literature review of case series. RESULTS: Of an estimated 6200 incident cancer cases (95% CI 6000-6500), 2500 (95% CI 2400-2700) were attributable to infection (attributable fraction = 40%, 95% CI 39-42). The most important infections were Kaposi sarcoma herpes virus, Epstein-Barr virus, and human papillomavirus, which together were responsible for 2200 new cancer cases (95% CI 2100-2400), mainly Kaposi sarcoma, lymphomas, and ano-genital cancers. The attributable fraction in HIV-infected people was highest in the age group 20-29 years (69%, 95% CI 65-72). MSM were the HIV transmission group with the highest attributable fraction (48%, 95% CI 46-50), due to the high incidence of both Kaposi sarcoma and anal cancer. CONCLUSION: The very high fraction of cancer attributable to infection in HIV-infected people points to special opportunities to prevent these cancers, that is, avoidance, detection, and early treatment of cancer-associated infections, and universal early detection and uninterrupted treatment of HIV infection to avoid immunosuppression.
Authors: Hilary A Robbins; Ruth M Pfeiffer; Meredith S Shiels; Jianmin Li; H Irene Hall; Eric A Engels Journal: J Natl Cancer Inst Date: 2015-02-06 Impact factor: 13.506
Authors: Gary M Clifford; Jerry Polesel; Martin Rickenbach; Luigino Dal Maso; Olivia Keiser; Andreas Kofler; Elisabetta Rapiti; Fabio Levi; Gernot Jundt; Thomas Fisch; Andrea Bordoni; Daniel De Weck; Silvia Franceschi Journal: J Natl Cancer Inst Date: 2005-03-16 Impact factor: 13.506
Authors: L Stewart Massad; Xianhong Xie; Gypsyamber D'Souza; Teresa M Darragh; Howard Minkoff; Rodney Wright; Christine Colie; Lorraine Sanchez-Keeland; Howard D Strickler Journal: Am J Obstet Gynecol Date: 2014-12-10 Impact factor: 8.661
Authors: Pragna Patel; Debra L Hanson; Patrick S Sullivan; Richard M Novak; Anne C Moorman; Tony C Tong; Scott D Holmberg; John T Brooks Journal: Ann Intern Med Date: 2008-05-20 Impact factor: 25.391
Authors: Gary M Clifford; Martin Rickenbach; Jerry Polesel; Luigino Dal Maso; Ingrid Steffen; Bruno Ledergerber; Andri Rauch; Nicole M Probst-Hensch; Christine Bouchardy; Fabio Levi; Silvia Franceschi Journal: AIDS Date: 2008-10-18 Impact factor: 4.177
Authors: Hugo De Vuyst; Gary M Clifford; Maria Claudia Nascimento; Margaret M Madeleine; Silvia Franceschi Journal: Int J Cancer Date: 2009-04-01 Impact factor: 7.396
Authors: Gary M Clifford; Martin Rickenbach; Mauro Lise; Luigino Dal Maso; Manuel Battegay; Julia Bohlius; Emmanuelle Boffi El Amari; Urs Karrer; Gernot Jundt; Andrea Bordoni; Silvia Ess; Silvia Franceschi Journal: Blood Date: 2009-03-31 Impact factor: 22.113
Authors: S Franceschi; L Dal Maso; M Rickenbach; J Polesel; B Hirschel; M Cavassini; A Bordoni; L Elzi; S Ess; G Jundt; N Mueller; G M Clifford Journal: Br J Cancer Date: 2008-07-29 Impact factor: 7.640
Authors: Julia M L Brotherton; Mark Jit; Patti E Gravitt; Marc Brisson; Aimée R Kreimer; Sara I Pai; Carole Fakhry; Joseph Monsonego; Silvia Franceschi Journal: Int J Cancer Date: 2016-03-22 Impact factor: 7.396
Authors: Álvaro H Borges; Jacqueline Neuhaus; Abdel G Babiker; Keith Henry; Mamta K Jain; Adrian Palfreeman; Peter Mugyenyi; Pere Domingo; Christian Hoffmann; Tim R H Read; Sanjay Pujari; Michael Meulbroek; Margaret Johnson; Timothy Wilkin; Ronald Mitsuyasu Journal: Clin Infect Dis Date: 2016-09-08 Impact factor: 9.079
Authors: David J Riedel; Kristen A Stafford; Aparna Vadlamani; Robert R Redfield Journal: AIDS Res Hum Retroviruses Date: 2016-12-13 Impact factor: 2.205